[Not Available].

P Nickers, B Frederick, C Louis, S Biver-Roisin, S Philippi, F Hertel, J Koy, M Untereiner
{"title":"[Not Available].","authors":"P Nickers,&nbsp;B Frederick,&nbsp;C Louis,&nbsp;S Biver-Roisin,&nbsp;S Philippi,&nbsp;F Hertel,&nbsp;J Koy,&nbsp;M Untereiner","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of the study: </strong>To evaluate the efficacy of fractionated stereotactic reirradiation with CyberKnife (CK) performed in 6 patients with high grade gliomas treated in Luxembourg with local recurrence (LR).</p><p><strong>Patients and methods: </strong>Between 04.2014 and 06.2016, 6 patients with multiform grade IV gliomas LR were reirradiated with CK (protocol CNER re-RT CFB 1), as reirradiation. The mean time between primary radiotherapy and local recurrence (LR) is 14.1 months [4 - 38]. CK is performed with a dose of 36 Gy in 6 fractions (5 cases) and 30 Gy in 3 fractions (1 case) Results : LR after CK (progression free survival) is 3.4 months [2 - 7] (5 cases assessment). Mean survival after CK is 12 months [3 - 22] (3 cases assessment). Mean survival after initial diagnosis is 37 months [17 - 58] (3 cases assessment). No toxicity is noticed (4 cases assessment). Time to first progression after primary treatment is a strong predictor for survival. Fractionated stereotactic reirradiation with CK is well tolerated and effective (survival) in patients with LR high grade gliomas. In accordance with these results, the CFB Conseil Scientifique recommends a new paradigm for MRI follow-up high grade gliomas. After first line treatment, an MRI has to be performed every 3 months, to identify LR earlier, and to offer the patients a way of salvage with CK option, in order to increase his chances of better survival.</p>","PeriodicalId":72476,"journal":{"name":"Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of the study: To evaluate the efficacy of fractionated stereotactic reirradiation with CyberKnife (CK) performed in 6 patients with high grade gliomas treated in Luxembourg with local recurrence (LR).

Patients and methods: Between 04.2014 and 06.2016, 6 patients with multiform grade IV gliomas LR were reirradiated with CK (protocol CNER re-RT CFB 1), as reirradiation. The mean time between primary radiotherapy and local recurrence (LR) is 14.1 months [4 - 38]. CK is performed with a dose of 36 Gy in 6 fractions (5 cases) and 30 Gy in 3 fractions (1 case) Results : LR after CK (progression free survival) is 3.4 months [2 - 7] (5 cases assessment). Mean survival after CK is 12 months [3 - 22] (3 cases assessment). Mean survival after initial diagnosis is 37 months [17 - 58] (3 cases assessment). No toxicity is noticed (4 cases assessment). Time to first progression after primary treatment is a strong predictor for survival. Fractionated stereotactic reirradiation with CK is well tolerated and effective (survival) in patients with LR high grade gliomas. In accordance with these results, the CFB Conseil Scientifique recommends a new paradigm for MRI follow-up high grade gliomas. After first line treatment, an MRI has to be performed every 3 months, to identify LR earlier, and to offer the patients a way of salvage with CK option, in order to increase his chances of better survival.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
(不可用)。
研究目的:评价射波刀(CK)分次立体定向再照射在卢森堡治疗的6例局部复发的高级别胶质瘤患者的疗效。患者和方法:2014年4月至2016年6月,对6例多发性IV级胶质瘤LR进行CK再照射(方案CNER re-RT CFB 1)。从初次放疗到局部复发(LR)的平均时间为14.1个月[4 - 38]。CK以36 Gy的剂量分6次(5例)和30 Gy的剂量分3次(1例)进行。结果:CK后的LR(无进展生存期)为3.4个月[2 - 7](5例评估)。术后平均生存期为12个月[3 - 22](3例评估)。初次诊断后的平均生存期为37个月[17 - 58](3例评估)。未见毒性反应(4例评估)。初次治疗后首次进展的时间是生存的一个强有力的预测指标。在LR高级别胶质瘤患者中,CK分次立体定向再照射具有良好的耐受性和有效性(生存率)。根据这些结果,CFB Conseil Scientifique推荐MRI随访高级别胶质瘤的新范例。在一线治疗后,必须每3个月进行一次MRI检查,以早期识别LR,并为患者提供CK选择的挽救方法,以增加其更好的生存机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Immune Network Case Report: Primary Spinal Lymphoma. [In process]. Treating the emotional and motivational inhibition of highly gifted underachievers with music psychotherapy: Meta-analysis of an evaluation study based on a sequential design. [In process]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1